TAVR or SAVR? What can we learn from a pooled meta-analysis of reconstructed time to event data?
Authors:
- 17 March 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 62 (1)
Abstract
Randomized clinical trials (RCTs) have compared transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) for the treatment of severe aortic valve stenosis in high-risk, intermediate-risk and low-risk patients since TAVR became clinically available. The results supported a stepwise expansion of the indication for TAVR from high-risk patients to intermediate-risk patients to low-risk patients. Consequently, the 2021 guidelines for the management of patients with valvular heart disease from the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery have been revised and now give a class I recommendation for TAVR for patients ≥75 years old regardless of additional comorbidities [ 1]. The 2020 American College of Cardiology/American Heart Association guideline for the management of patients with valvular heart disease even gives a class I recommendation for transfemoral TAVR for patients ≥65 years old after interdisciplinary patient assessment considering patient longevity and valve durability [ 2...Keywords
This publication has 5 references indexed in Scilit:
- Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical RiskJACC, 2021
- Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve ReplacementNew England Journal of Medicine, 2020
- Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI TrialJACC: Cardiovascular Interventions, 2020
- Five-Year Clinical and Echocardiographic Outcomes From the NOTION Randomized Clinical Trial in Patients at Lower Surgical RiskCirculation, 2019
- Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk PatientsNew England Journal of Medicine, 2019